Impact of Estrogen Signaling on Tumor Immunity and Response to Immune Therapy in Ovarian Cancer

Abstract

Immune therapy has been a major breakthrough in cancer treatment, however the benefit for women with ovarian cancer has been limited. Our prior work demonstrated that modifying conditions in the tumor environment can significantly improve treatment with immune therapy in ovarian cancer models. Identifying new strategies to modify the tumor environment is expected to allow women with ovarian cancer to optimally benefit from immune therapy.The hormone estrogen impacts immune function in both healthy people and in cancer models. Estrogen receptors on tumor cells have been targeted for ovarian cancer treatment, but the impact of estrogen on immune cells in the ovarian tumor environment is not known. We sought to test whether selective agents targeting distinct estrogen signaling pathways can enhance the effects of immune therapy in ovarian cancer.Results to date indicate that estrogen signaling impacts both tumor cell and immune cell viability and function. Our long-term goal is to identify a combination of estrogen signaling agents and immune checkpoint antibodies that optimally induce an immune response against ovarian cancer.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Aug 01, 2023
Accession Number
AD1216514

Entities

People

  • Sarah Adams

Organizations

  • University of New Mexico

Tags

DTIC Thesaurus Topics

  • Antibodies
  • Biomedical Research
  • Blockades
  • Cells
  • Department Of Defense
  • Diseases
  • Hormone Antagonists
  • Immunity
  • Immunomodulation
  • Inhibition
  • Lymphocytes
  • Medical Personnel
  • Neoplasms
  • Ovarian Cancer
  • Students
  • Therapy
  • Viability

Fields of Study

  • Biology

Readers

  • Distributed Systems and Data Platform Development
  • Molecular and Cellular Biology
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.